Saturday 17 October 2026
Export VRCA’s income statement to Excel — free account
Verrica Pharmaceuticals Inc.
VRCA Healthcare Biotechnology
Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3,200.0%, free cash flow grew 7.63% and total debt fell 97.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.54
0.24
−6.35%
Follow VRCA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 1 | 3 | 6 |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | 0.00 | 6.49 | (2.44) | (10.99) | (6.71) |
P/S ratio |
— | — | — | — | — | 0.00 | 10.89 | 60.26 | 4.79 | 2.49 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (5.21) | (0.92) | (9.42) | (24.15) | (19.42) |
P/Operating CF |
— | — | — | — | — | (28.48) | (19.86) | (21.28) | (2.26) | (19.28) |
Beneish M-Score |
— | — | — | — | — | — | — | 6.59 | (4.24) | 14.25 |
P/B ratio |
— | — | — | — | — | 7.60 | 2.46 | 15.62 | 0.00 | 3.58 |
Price to Tangible BV |
— | — | — | — | — | 7.60 | 2.46 | 15.62 | 0.00 | 3.58 |
EV/Sales |
— | — | — | — | — | 0.00 | 7.27 | 55.32 | 4.58 | 2.01 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | (7.94) | (3.52) | (7.35) | (0.57) | (4.05) |
EV/FCF |
— | — | — | — | — | (7.64) | (3.43) | (7.28) | (0.57) | (4.00) |
Quick Ratio |
1.26 | 14.06 | 36.26 | 18.51 | 1.66 | 1.53 | 10.05 | 4.34 | 1.60 | 2.16 |
Current Ratio |
1.30 | 14.75 | 36.80 | 19.39 | 1.71 | 1.61 | 11.31 | 4.55 | 1.76 | 2.59 |
Net Debt/EBITDA |
0.28 | 1.94 | 4.11 | 2.07 | 0.71 | 0.94 | 1.60 | 0.40 | 0.03 | 2.59 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.27% | 49.91% | 52.05% | 3.41% | 53.80% | 82.55% | 1.36% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 1.12 | 1.28 | 0.04 | 2.22 | (4.53) | 0.03 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.14 | 0.08 | 0.11 | 0.70 |
Operating CF/Net income |
0.84 | 0.47 | 0.87 | 0.97 | 0.71 | 0.79 | 0.76 | 0.58 | 0.80 | 0.99 |
Capex/Depreciation |
— | — | (38.70) | (7.42) | (7.38) | (2.01) | (0.58) | (0.43) | (0.01) | 0.00 |
Interest Coverage |
— | (2,228.50) | (17.77) | (16.03) | (13.24) | (7.20) | (9.80) | (16.60) | (7.00) | (1.57) |
| 39.42% | 201.11% | (50.12%) | (36.53%) | (87.13%) | (106.97%) | (67.42%) | (224.08%) | (1,546.58%) | (240.35%) | |
| (39.74%) | (202.74%) | (40.89%) | (35.19%) | (59.89%) | (45.48%) | (39.23%) | (106.07%) | (112.84%) | (35.33%) | |
ROIC |
0.00% | 0.00% | 0.00% | (590.08%) | (555.11%) | (487.82%) | (182.68%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(1,530.40%) | (115.26%) | (23.22%) | (44.27%) | (136.50%) | (109.06%) | (61.92%) | (108.83%) | (336.52%) | (67.98%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 19.68 | 314.57 | 3.71 | 55.37 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 132.74% | 135.05% | 396.08% | 156.49% | 24.89% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 224.83% | 192.70% | 923.20% | 777.45% | 99.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 50.44% | 55.19% | 280.56% | 94.69% | 9.33% |
Graham Net Nets |
— | — | — | — | — | 0.11 | 0.35 | 0.05 | (0.35) | 0.23 |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 25.68 | 0.00 |
Earnings Yield |
— | — | — | — | — | (14.08%) | (28.40%) | (21.44%) | (220.00%) | (19.01%) |
Free Cash Flow Yield |
— | — | — | — | — | (11.57%) | (19.45%) | (12.61%) | (168.68%) | (20.19%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.44 | 2.64 | 1.13 | 1.46 | 3.34 |
Operating CF per Share |
(4.37) | (16.08) | (12.19) | (11.01) | (12.08) | (10.20) | (5.46) | (8.51) | (11.76) | (1.65) |
Capex per Share |
0.00 | 0.00 | (0.53) | (0.77) | (0.68) | (0.40) | (0.14) | (0.08) | 0.00 | 0.00 |
Free Cash Flow per Share |
(4.37) | (16.08) | (12.72) | (11.77) | (12.76) | (10.60) | (5.60) | (8.59) | (11.76) | (1.65) |
Cash per Share |
1.43 | 30.40 | 61.25 | 24.91 | 26.19 | 26.01 | 10.03 | 15.34 | 8.94 | 2.83 |
Shareholders Equity per Share |
0.34 | 29.71 | 60.99 | 26.11 | 13.20 | 12.06 | 11.72 | 4.36 | (1.90) | 2.32 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.34 | 29.71 | 60.99 | 26.11 | 13.20 | 12.06 | 11.72 | 4.36 | (1.90) | 2.32 |
Free Cash Flow |
(1.61) | (4.58) | (18.65) | (29.31) | (31.90) | (28.67) | (19.13) | (38.94) | (60.95) | (17.63) |
Working Capital |
0.13 | 8.47 | 88.68 | 61.63 | 28.18 | 28.27 | 35.66 | 60.51 | 22.17 | 26.10 |
Capital Expenditures |
— | — | (0.77) | (1.91) | (1.69) | (1.08) | (0.48) | (0.36) | (0.02) | — |
Net Current Asset Value |
0.13 | 8.47 | 88.68 | 61.57 | 26.48 | 26.81 | 34.43 | 15.70 | (12.81) | 20.15 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.09 | 0.05 | 0.07 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | 0.08 | 0.12 | 0.07 | 0.14 | 0.21 | 0.79 | 2.15 | 3.74 |
Cash ROIC |
(247.09%) | (26.75%) | (10.40%) | (23.04%) | (23.55%) | (19.82%) | (25.23%) | (29.23%) | (75.10%) | (31.74%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 2.09 | 3.37 | 13.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.04 | 0.24 | 0.30 | 0.79 | 1.07 | 0.50 | 1.26 | 1.73 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57 | 1.46 |
Average Days of Payables |
0.00 | 0.00 | 17,261.08 | 1,681.67 | 554.67 | 653.44 | 255.25 | 1,205.58 | 252.57 | 219.78 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.04 | 328.10 | 237.18 |
Average Receivables |
— | — | — | — | — | — | — | 2.45 | 2.25 | 2.74 |
Average Payables |
0.14 | 0.14 | 0.56 | 1.07 | 0.77 | 0.60 | 0.68 | 1.49 | 2.18 | 1.98 |
Average Inventory |
— | — | — | — | — | — | — | — | 1.74 | 2.35 |
Average Assets |
4.81 | 4.81 | 50.49 | 80.17 | 71.29 | 77.14 | 62.42 | 63.16 | 67.87 | 50.63 |
Average Common Equity |
(4.85) | (4.85) | 41.19 | 77.22 | 49.00 | 32.80 | 36.32 | 29.90 | 4.95 | 7.44 |
Columns are period end dates